Quantamental Technologies LLC Buys Shares of 3,953 Nextgen Healthcare Inc (NXGN)

Quantamental Technologies LLC bought a new position in Nextgen Healthcare Inc (NASDAQ:NXGN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 3,953 shares of the company’s stock, valued at approximately $60,000.

Several other large investors have also added to or reduced their stakes in the company. Hanson & Doremus Investment Management bought a new position in Nextgen Healthcare in the 3rd quarter worth about $208,000. AQR Capital Management LLC bought a new position in Nextgen Healthcare in the 3rd quarter worth about $12,649,000. GSA Capital Partners LLP bought a new position in Nextgen Healthcare in the 3rd quarter worth about $723,000. Investment Counselors of Maryland LLC bought a new position in Nextgen Healthcare in the 3rd quarter worth about $24,953,000. Finally, Dimensional Fund Advisors LP bought a new position in Nextgen Healthcare in the 3rd quarter worth about $47,298,000. 68.99% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on NXGN. Zacks Investment Research upgraded shares of Nextgen Healthcare from a “sell” rating to a “hold” rating in a research note on Wednesday, December 5th. TheStreet cut shares of Nextgen Healthcare from a “b-” rating to a “c+” rating in a research note on Wednesday, November 21st. Cantor Fitzgerald reiterated a “buy” rating and issued a $23.00 price target on shares of Nextgen Healthcare in a research note on Thursday, December 6th. KeyCorp dropped their price target on shares of Nextgen Healthcare from $17.00 to $16.00 and set an “underweight” rating on the stock in a research note on Wednesday, October 31st. Finally, Morgan Stanley upgraded shares of Nextgen Healthcare from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $12.00 to $16.00 in a research note on Thursday, November 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $18.50.

NXGN opened at $17.17 on Monday. Nextgen Healthcare Inc has a 52-week low of $12.24 and a 52-week high of $23.73. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 30.12, a P/E/G ratio of 3.37 and a beta of 1.11. The company has a current ratio of 1.32, a quick ratio of 1.31 and a debt-to-equity ratio of 0.07.

ILLEGAL ACTIVITY WARNING: This story was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.wkrb13.com/2019/02/11/quantamental-technologies-llc-buys-shares-of-3953-nextgen-healthcare-inc-nxgn.html.

About Nextgen Healthcare

NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.

Featured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Want to see what other hedge funds are holding NXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nextgen Healthcare Inc (NASDAQ:NXGN).

Institutional Ownership by Quarter for Nextgen Healthcare (NASDAQ:NXGN)

Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply